Baird lowered the firm’s price target on Thermo Fisher to $620 from $621 and keeps an Outperform rating on the shares. The firm said 1Q results were ahead of expectations, helped by strong Lab Products and Biopharma Services performance, and they raised low-end FY24 revenue/EPS guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
